Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026

Altimmune announced 48-week data from its IMPACT Phase 2b trial showing that pemvidutide, a glucagon/GLP-1 dual receptor agonist, significantly reduced triglycerides (-23.7%), total cholesterol (-15.4%), and improved weight loss (7.5%), blood pressure, and waist circumference in MASH patients. The drug demonstrated a favorable safety profile with minimal discontinuations due to adverse events. The company plans to initiate the PERFORMA Phase 3 trial in the second half of 2026.